Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 10/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.41 |
| ▸ | WNT1 | P04628 | 8/20 | 0.41 |
| ▸ | ESRRG | P62508 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.38 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | HCK | P08631 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17795637 | 0.80 | GSK3B (0.46) | GSK3BDYRK1AWNT1SRC | |
| SCHEMBL22053089 | 0.78 | KMO (0.44) | MAPTKDM1AKDM4ENPC1PKM | |
| SCHEMBL28298649 | 0.77 | HSD17B1 (0.50) | MAPTGSK3BDYRK1AWNT1KDM4C | |
| SCHEMBL9143504 | 0.74 | KDR (0.50) | MAPTKDM4EKDM5CSRCKDR | |
| SCHEMBL13872400 | 0.74 | HSD17B1 (0.44) | GSK3BDYRK1AWNT1KDM4CKDM4E | |
| SCHEMBL21955600 | 0.73 | KDM4E (0.41) | GSK3BDYRK1AWNT1KDM4CKDM4E | |
| SCHEMBL1630249 | 0.73 | ESRRG (0.65) | GSK3BESRRGKDREPHB4NPC1 | |
| Ammonia Solution, Strong SCHEMBL28862432 | 0.73 | KDR (0.49) | MAPTKDM4EKDM5CSRCKDR | |
| SCHEMBL15542994 | 0.72 | GSK3B (0.44) | GSK3BDYRK1AWNT1KDM4CKDM4E | |
| SCHEMBL12277854 | 0.72 | TEK (0.53) | KDM4ESRCKDREPHB4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932390-B2 | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932390-B2 | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932390-B2 | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2038288-B1 | NOVEL 4-AMINO-3-(-AZOLYL-PHENOXYMETHYL)-THIENOÝ3,2¨PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-11-24 | — | — | EP | disclosed |
| EP-2038288-A1 | NOVEL 4-AMINO-3-(-AZOLYL-PHENOXYMETHYL)-THIENOÝ3,2¨PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-20080009515-A1 | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives | CHEN YI | 2008-01-10 | — | — | US | disclosed |
| US-20080009515-A1 | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives | CHEN YI | 2008-01-10 | — | — | US | disclosed |
| US-20080009515-A1 | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives | CHEN YI | 2008-01-10 | — | — | US | disclosed |
| WO-2008000697-A1 | NOVEL 4-AMINO-3-(-AZOLYL-PHENOXYMETHYL)-THIENO[3,2]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009515-A1 | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives | UQCRB, UQCRC2, AURKB | MAPT 4268/4885SNCA 1649/4885GSK3B 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.